In Reply
Arch Pathol Lab Med. 2024 May 1;148(5):507. doi: 10.5858/arpa.2024-0067-LE.NO ABSTRACTPMID:38662905 | DOI:10.5858/arpa.2024-0067-LE (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 25, 2024 Category: Laboratory Medicine Authors: Alexander Craig Mackinnon Shuko Harada Source Type: research

Clarification of Information in "Navigating Next-Generation Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance Tests"
Arch Pathol Lab Med. 2024 May 1;148(5):507. doi: 10.5858/arpa.2023-0593-LE.NO ABSTRACTPMID:38662906 | DOI:10.5858/arpa.2023-0593-LE (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 25, 2024 Category: Laboratory Medicine Authors: Christina M Lockwood Source Type: research

The Cancer Biomarkers Conference: Pathologists Leading the Molecular Testing Discussion
Arch Pathol Lab Med. 2024 May 1;148(5):e75-e76. doi: 10.5858/arpa.2023-0175-ED.NO ABSTRACTPMID:38662907 | DOI:10.5858/arpa.2023-0175-ED (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 25, 2024 Category: Laboratory Medicine Authors: Timothy Craig Allen Source Type: research

Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology
CONCLUSIONS.—: In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2.PMID:38649148 | DOI:10.5858/arpa.2023-0543-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Fatih Mert Do ğukan H üseyin Karatay Sabahattin Y üzkan Şebnem Burhan Buru ç Erkan Banu Y ılmaz-Özgüven Source Type: research

Democratizing Artificial Intelligence in Anatomic Pathology
CONCLUSIONS.—: Democratizing artificial intelligence by creating an ecosystem to support pathologists with varying levels of expertise can break down entry barriers, reduce overall cost of algorithm development, improve algorithm quality, and enhance the speed of adoption.PMID:38649149 | DOI:10.5858/arpa.2023-0205-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Thomas J Flotte Stephanie A Derauf Rachel K Byrd Trynda N Kroneman Debra A Bell Lucas Stetzik Seung-Yi Lee Alireza Samiei Steven N Hart Joaquin J Garcia Gillian Beamer Thomas Westerling-Bui Source Type: research

Screening and Diagnosis of Rare Thalassemia Variants
CONCLUSIONS.—: Rare thalassemia variants are more common than previously thought. Despite advancements in TGS, there is still no foolproof method for detection of all types of thalassemia. Thus, a comprehensive approach is necessary for accurate screening and diagnosis of rare thalassemia variants.PMID:38649152 | DOI:10.5858/arpa.2023-0382-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Haishen Tang Yi Xiong Jiaqi Tang Xiaohong Wang Ya Wang Liping Huang Runli Wang Degang Wang Source Type: research

Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology
CONCLUSIONS.—: In conclusion, NKX2.2 is a transcription factor that can be used as an additional tool in pituitary pathology, and PIT1 and SF1-multilineage PitNETs are specific tumors that usually present with acromegaly, show signs of a nonaggressive clinical course, have a pseudopapillary histomorphology, and express NKX2.2.PMID:38649148 | DOI:10.5858/arpa.2023-0543-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Fatih Mert Do ğukan H üseyin Karatay Sabahattin Y üzkan Şebnem Burhan Buru ç Erkan Banu Y ılmaz-Özgüven Source Type: research

Democratizing Artificial Intelligence in Anatomic Pathology
CONCLUSIONS.—: Democratizing artificial intelligence by creating an ecosystem to support pathologists with varying levels of expertise can break down entry barriers, reduce overall cost of algorithm development, improve algorithm quality, and enhance the speed of adoption.PMID:38649149 | DOI:10.5858/arpa.2023-0205-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Thomas J Flotte Stephanie A Derauf Rachel K Byrd Trynda N Kroneman Debra A Bell Lucas Stetzik Seung-Yi Lee Alireza Samiei Steven N Hart Joaquin J Garcia Gillian Beamer Thomas Westerling-Bui Source Type: research

Screening and Diagnosis of Rare Thalassemia Variants
CONCLUSIONS.—: Rare thalassemia variants are more common than previously thought. Despite advancements in TGS, there is still no foolproof method for detection of all types of thalassemia. Thus, a comprehensive approach is necessary for accurate screening and diagnosis of rare thalassemia variants.PMID:38649152 | DOI:10.5858/arpa.2023-0382-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 22, 2024 Category: Laboratory Medicine Authors: Haishen Tang Yi Xiong Jiaqi Tang Xiaohong Wang Ya Wang Liping Huang Runli Wang Degang Wang Source Type: research

The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients
CONCLUSIONS.—: Small-size CTCs are a reliable prognostic indicator and a probable predictor of the severity of disease in NSCLC patients.PMID:38631685 | DOI:10.5858/arpa.2023-0455-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 17, 2024 Category: Laboratory Medicine Authors: Qianqian Sun Weiqing Li Donghua Yang Peter Ping Lin Lina Zhang Huiqin Guo Source Type: research

Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma: A Study of 21 Institutions
CONCLUSIONS.—: The data from this study provide multi-institutional benchmark data to assist laboratories performing periodic comparisons as part of a quality management program. Overall expression rates were generally similar to those of other published reports, with the exception of the ER-negative and HER2-positive rates, both of which were somewhat lower.PMID:38631690 | DOI:10.5858/arpa.2022-0384-CP (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 17, 2024 Category: Laboratory Medicine Authors: Daniel D Mais Alia N Nazarullah Anthony J Guidi Suzanne Dintzis Barbara J Blond Thomas A Long Suzanne N Coulter Richard W Brown Source Type: research

The Presence of Small-Size Circulating Tumor Cells Predicts Worse Prognosis in Non-Small Cell Lung Cancer Patients
CONCLUSIONS.—: Small-size CTCs are a reliable prognostic indicator and a probable predictor of the severity of disease in NSCLC patients.PMID:38631685 | DOI:10.5858/arpa.2023-0455-OA (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 17, 2024 Category: Laboratory Medicine Authors: Qianqian Sun Weiqing Li Donghua Yang Peter Ping Lin Lina Zhang Huiqin Guo Source Type: research

Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma: A Study of 21 Institutions
CONCLUSIONS.—: The data from this study provide multi-institutional benchmark data to assist laboratories performing periodic comparisons as part of a quality management program. Overall expression rates were generally similar to those of other published reports, with the exception of the ER-negative and HER2-positive rates, both of which were somewhat lower.PMID:38631690 | DOI:10.5858/arpa.2022-0384-CP (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 17, 2024 Category: Laboratory Medicine Authors: Daniel D Mais Alia N Nazarullah Anthony J Guidi Suzanne Dintzis Barbara J Blond Thomas A Long Suzanne N Coulter Richard W Brown Source Type: research

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
CONCLUSIONS.—: This guideline summarizes the current understanding and hurdles associated with the use of PD-L1 expression and TMB testing for immune checkpoint inhibitor therapy selection in patients with advanced non-small cell lung cancer and presents evidence-based recommendations for PD-L1 and TMB testing in the clinical setting.PMID:38625026 | DOI:10.5858/arpa.2023-0536-CP (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 16, 2024 Category: Laboratory Medicine Authors: Lynette M Sholl Mark Awad Upal Basu Roy Mary Beth Beasley Richard Walter Cartun David M Hwang Gregory Kalemkerian Fernando Lopez-Rios Mari Mino-Kenudson Ajit Paintal Kearin Reid Lauren Ritterhouse Lesley A Souter Paul E Swanson Christina B Ventura Larissa Source Type: research

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation
CONCLUSIONS.—: This guideline summarizes the current understanding and hurdles associated with the use of PD-L1 expression and TMB testing for immune checkpoint inhibitor therapy selection in patients with advanced non-small cell lung cancer and presents evidence-based recommendations for PD-L1 and TMB testing in the clinical setting.PMID:38625026 | DOI:10.5858/arpa.2023-0536-CP (Source: Archives of Pathology and Laboratory Medicine)
Source: Archives of Pathology and Laboratory Medicine - April 16, 2024 Category: Laboratory Medicine Authors: Lynette M Sholl Mark Awad Upal Basu Roy Mary Beth Beasley Richard Walter Cartun David M Hwang Gregory Kalemkerian Fernando Lopez-Rios Mari Mino-Kenudson Ajit Paintal Kearin Reid Lauren Ritterhouse Lesley A Souter Paul E Swanson Christina B Ventura Larissa Source Type: research